Table 4.
Results of network meta-analysis: all treatments versus placebo without covariates
| Trough FEV1L difference in CFB (95% CrI) at 12 weeks | Trough FEV1L difference in CFB (95% CrI) at 6 months | SGRQ total score difference in CFB (95% CrI) at 6 months | TDI total score difference (95% CrI) at 6 months | |
|---|---|---|---|---|
| All studies | ||||
| IND 150 μg | 0.17 (0.15, 0.20) | 0.16 (0.13, 0.19) | −4.43 (−6.67, −2.17) | 1.01 (0.65, 1.37) |
| IND 300 μg | 0.17 (0.15, 0.20) | 0.16 (0.13, 0.19) | −3.01 (−5.26, −0.81) | 1.19 (0.83, 1.55) |
| SAL/FP 50/500 μg | 0.14 (0.13, 0.16) | 0.16 (0.13, 0.19) | −2.27 (−4.33, −0.50) | 1.70 (1.11, 2.29) |
| SAL/FP 50/250 μg | 0.16 (0.10, 0.21) | 0.16 (0.10, 0.22) | NR | 0.80 (0.11, 1.49) |
| FOR/BUD 9/320 μg | 0.09 (0.07, 0.11) | 0.08 (0.06, 0.10) | −4.03 (−6.46, −1.60) | NR |
| FOR/BUD 9/160 μg | 0.07 (0.05, 0.09) | 0.06 (0.04, 0.09) | −2.95 (−6.33, 0.40) | NR |
| All studies excluding 3 Asian studies | ||||
| IND 150 μg | 0.18 (0.16, 0.21) | 0.18 (0.14, 0.21) | −4.89 (−7.35, −2.47) | 1.10 (0.67, 1.53) |
| IND 300 μg | 0.17 (0.14, 0.21) | 0.17 (0.14, 0.21) | −3.20 (−5.67, −0.84) | 1.26 (0.83, 1.69) |
| SAL/FP 50/500 μg | 0.14 (0.12, 0.16) | 0.15 (0.12, 0.18) | −1.44 (−3.39, 0.58) | 1.70 (1.10, 2.29) |
| SAL/FP 50/250 μg | 0.16 (0.10, 0.21) | 0.16 (0.10, 0.22) | NR | 0.80 (0.11, 1.49) |
| FOR/BUD 9/320 μg | 0.09 (0.07, 0.11) | 0.08 (0.06, 0.10) | −4.02 (−6.25, −1.80) | NR |
| FOR/BUD 9/160 μg | 0.07 (0.05, 0.09) | 0.06 (0.04, 0.09) | −2.96 (−6.05, 0.13) | NR |
Abbreviations: CFB, change from baseline; CrI, 95% credibility interval; FEV1, forced expiratory volume in 1 second; FOR/BUD, fixed-dose formoterol and budesonide; IND, indacaterol; NR, not reported; SAL/FP, fixed-dose salmeterol and fluticasone proprionate; SGRQ, St. George’s Respiratory Questionnaire; TDI, Transition Dyspnea Index.